Table 2.
Demographics and clinical characteristic | Primary non-responders (n = 17) | Primary responders (n = 119) | P-valuea |
---|---|---|---|
Sex | – | – | 0.377 |
Male, n (%) | 11 (64.7) | 90 (75.6) | – |
Female, n (%) | 6 (35.3) | 29 (24.4) | – |
Age, years, median [IQR] | 23.0 [15.5–32.0] | 23.0 [18.0–28.0] | 0.916 |
BMI, kg/m2, median [IQR] | 18.6 [16.5–20.4] | 18.0 [16.4–19.5] | 0.525 |
Disease duration, years, median [IQR] | 2.0 [0.8–3.0] | 1.0 [0.5–3.0] | 0.468 |
Disease behavior, n (%) | – | – | 0.431 |
B1 | 13 (76.5) | 98 (82.4) | – |
B2 | 1 (5.9) | 8 (6.7) | – |
B3 | 3 (17.6) | 10 (8.4) | – |
B2 + B3 | 0 (0) | 3 (2.5) | – |
Disease location, n (%) | – | – | 0.621 |
L1 | 0 (0) | 10 (8.4) | – |
L2 | 1 (5.9) | 3 (2.5) | – |
L3 | 15 (88.2) | 92 (77.3) | – |
L1 + L4 | 0 (0) | 2 (1.7) | – |
L2 + L4 | 0 (0) | 0 (0) | – |
L3 + L4 | 1 (5.9) | 12 (10.1) | |
Perianal lesions, n (%) | 14 (82.4) | 91 (76.5) | 0.762 |
Previous bowel surgery, n (%) | 1 (5.9) | 16 (13.4) | 0.695 |
Combined with thiopurine, n (%) | 9 (52.9) | 69 (59.0) | 0.694 |
Albumin at baseline, g/L, mean ± SD | 36.1 [31.7–39.7] | 38.4 [34.5–42.1] | 0.111 |
Hemoglobin at baseline, mg/dL, mean ± SD | 115.0 [93.0–127.5] | 114.0 [95.0–126.4] | 0.851 |
hs-CRP at baseline, mg/L, median [IQR] | 12.1 [9.2–33.0] | 11.8 [9.5–18.8] | 0.512 |
ESR at baseline, mm/h, median [IQR] | 55.0 [41.0–68.5] | 38.5 [27.0–64.0] | 0.038 |
CRP at baseline, mg/L, median [IQR] | 22.6 [7.4–50.2] | 20.0 [10.6–38.7] | 0.911 |
CRP at 14th week, mg/L, median [IQR] | 9.4 [2.9–28.4] | 1.0 [0.5–3.8] | <0.001 |
IFX level at 14th week, μg/mL, median [IQR] | 1.7 [0.6–4.0] | 3.3 [1.3–6.0] | 0.042 |
BMI, body mass index; B1, non-stricturing non-penetrating; B2, structuring; B3, penetrating; L1, terminal ileum; L2, colon; L3, ileocolon; L4, upper gastrointestinal; hs-CRP, high sensitive C reaction protein; IFX, infliximab.
Chi-square tests or Mann–Whitney U test; those P-values <0.05 are highlighted in bold font.